Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis

• Main Authors: Jagadeswara Rao Earla (Author), George J. Hutton (Author), J. Douglas Thornton (Author), Hua Chen (Author), Michael L. Johnson (Author), Rajender R. Aparasu (Author)
• Format: Book
• Published: Elsevier, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years. Objective: The objective of this study was to examine the facto...